Comparative Pharmacology
Head-to-head clinical analysis: BROMFENAC SODIUM versus PROLENSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMFENAC SODIUM versus PROLENSA.
BROMFENAC SODIUM vs PROLENSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever. Specifically, bromfenac is a potent inhibitor of COX-2.
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby decreasing inflammation, pain, and angiogenesis in the eye.
One drop (0.1 mL) of 0.09% ophthalmic solution (bromfenac 0.9 mg/mL) instilled into the affected eye(s) twice daily beginning 24 hours before cataract surgery and continuing on the day of surgery and for 14 days postoperatively.
Adults: 1 drop in affected eye(s) twice daily (morning and evening) for 2 weeks.
None Documented
None Documented
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment; clinical context: short half-life supports twice-daily dosing in ophthalmic use)
Terminal elimination half-life is approximately 1.5 hours for the ocular route; after systemic absorption, half-life is about 4.5 hours. The short half-life limits systemic exposure but requires multiple daily dosing for sustained ocular effect.
Renal: ~80% (primarily as unchanged drug and glucuronide conjugate); Biliary/Fecal: ~20%
Primarily renal elimination (approximately 70% of the dose as unchanged drug and metabolites), with the remainder excreted in feces via biliary secretion (approximately 30%).
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID